Executive Summary
Across the 44 filings for the S&P BSE PHARMA constituent set dated 4 November 2026, the dominant theme is a sharp divergence between top-line growth and bottom-line compression.
Zydus Lifesciences (consolidated revenue +29% YoY to Rs 79,096 mn, PAT -26.6% to Rs 9,255 mn), Lupin (consolidated revenue +11.1% but PAT -22.2%, EBITDA margin down ~770 bps to 27.9%), Biocon (consolidated profit -57% YoY on +2% revenue) and Apollo Hospitals (revenue +23%, PAT up on a consolidated basis but standalone other expenses +27.7%) all show revenue growth outpacing or disconnected from earnings. Margin compression is the common thread: Zydus EBITDA margin fell to 24.0% from 32.9%, Lupin to 25.1% from 31.3% (EBITDA-basis), and Biocon EBITDA margin to 20% from 22%. Management commentary points to US competition, loss of exclusivity (Lupin, Sun Pharma's lenalidomide erosion), currency headwinds (GSK India) and rising employee and finance costs. On the positive side, Aurobindo Pharma delivered record quarterly revenue of Rs 10,263 Cr (+23.9% YoY) and EBITDA margin of 21.0%, and declared a Rs 7 interim dividend, while Zydus completed the Sterling Biotech API acquisition. Sentiment across the set is predominantly mixed, and near-term catalysts include the Alkem results on 12 November, the Aurobindo dividend record date of 11 November, the Sun Pharma Organon closing in Q4 FY27, and Glenmark's ASH presentation on 12 December.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Board meeting · Company update · M&A · Corporate governance · Corporate action
Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from November 03, 2026.
Investment Signals (13)
- Aurobindo Pharma ↓ (BULLISH)▲
Record Q2 FY27 consolidated revenue of Rs 10,263 Cr (+23.9% YoY, +12.2% QoQ), EBITDA Rs 2,156 Cr at 21.0% margin (+75 bps YoY), PAT Rs 1,124 Cr (+32.5% YoY), plus Rs 7/share interim dividend with record date 11 Nov 2026
-
Standalone PAT +24.3% YoY to Rs 723.6 Cr, but standalone other income fell ~35.5% YoY and Growth Markets revenue slipped 3.5% QoQ, so quality of growth is partly acquisition-driven (Lannett consolidated from 29 June 2026) [BULLISH with caveat]
- Zydus Lifesciences ↓ (BEARISH)▲
Consolidated revenue +29.2% YoY to Rs 79,096 mn across Consumer Wellness (+76.1%), North America (+20.8%) and International (+33.6%), but Q2 PBT -25.5% YoY and net profit -26.6% YoY, with Q2 revenue -1.3% QoQ
- Zydus Lifesciences ↓ (BEARISH)▲
Standalone net profit -38.2% YoY as subsidiary dividend income collapsed to Rs 220 mn from Rs 4,198 mn; earnings quality is weaker than headline revenue suggests
- Lupin ↓ (BEARISH)▲
Consolidated PAT -22.2% YoY to Rs 11,553 mn on +11.1% revenue, with EBITDA margin down ~770 bps to 27.9%; US sales fell 12.1% QoQ on competition and LOE, and cash balance fell to Rs 19,391 mn from Rs 41,677 mn after Rs 20,397 mn of acquisition payments
- Lupin ↓ (MIXED)▲
Net cash position of Rs (33,490) mn (net debt/equity -0.14) provides balance-sheet flexibility despite earnings pressure, though standalone exceptional charges (Rs 769 mn impairment, Rs 3,163 mn antitrust settlement) warrant monitoring
- Biocon ↓ (BEARISH)▲
Consolidated profit for the period -57% YoY to Rs 567 mn; Biosimilars segment PBT collapsed to Rs 325 mn from Rs 1,672 mn YoY and Services revenue fell 8.6% YoY, while management frames FY27 as a transition year with stronger H2 expected
- ▲
Standalone PAT +29% YoY to Rs 917 mn and H1 standalone net profit to Rs 1,439 mn from Rs 626 mn, with Generics losses narrowing to Rs (304) mn from Rs (692) mn [BULLISH on standalone/Generics]
- Apollo Hospitals ↓ (MIXED-BULLISH)▲
Consolidated revenue +23.1% YoY to Rs 76,149 mn and consolidated PAT +33.5%; Digital health & pharmacy segment result +101% YoY and Healthcare services segment +20.3%, but consolidated trade receivables rose to Rs 42,562 mn from Rs 34,849 mn since March 2026
- Apollo Hospitals ↓ (BEARISH)▲
Standalone capex of Rs 6,655 mn and debt repayment of Rs 977 mn outpaced Rs 11,115 mn operating cash flow, reducing cash to Rs 2,767 mn from Rs 3,426 mn; CEO exit for Hospitals Division effective 14 Nov 2026 adds leadership transition risk
- Sun Pharmaceutical ↓ (MIXED)▲
Consolidated sales +11.8% YoY to INR 1,61,000 mn, but US sales -8.2% to USD 455 mn on lenalidomide erosion and Ilumya slowdown, with reported PAT Rs 19,885 mn vs adjusted Rs 31,620 mn; Organon acquisition on track for Q4 FY27 close
- Glenmark Pharmaceuticals ↓ (BULLISH)▲
Partnered trispecific ISB 2001 (AbbVie licence, July 2025) gets an ASH oral presentation on 12 Dec 2026, a clinical catalyst with no near-term financial disclosure
- GSK Pharmaceuticals (MIXED)▲
Q2 FY27 revenue Rs 1,180 cr (+21% YoY), EBITDA +33% YoY, but PAT margin expansion of 260 bps was partly driven by interest on an income tax refund, and several vaccine brands lost unit share (Fluarix -5.2%, Boostrix -3.6%)
Risk Flags (9)
- Lupin/Margin and LOE Risk↓ [HIGH RISK]▼
EBITDA margin collapsed from 31.3% to 25.1% YoY (Q2 FY27) and US sales fell 12.1% QoQ on increased competition and loss of exclusivity on key products; employee costs +28.8% YoY to Rs 14,236 mn
- Zydus Lifesciences/Earnings Quality↓ [HIGH RISK]▼
Standalone PAT -38.2% YoY on lower subsidiary dividends; consolidated Medical Technologies loss widened to Rs (928) mn from Rs (345) mn; finance costs +85% YoY to Rs 1,870 mn
- Biocon/Profitability Collapse↓ [HIGH RISK]▼
Consolidated profit -57% YoY, PBT before exceptional items -66% YoY to Rs 62 cr, Biosimilars Q2 EBITDA -14% QoQ on revenue recognition timing; D&A +19% YoY
- Apollo Hospitals/Cost and Cash Pressure↓ [MEDIUM-HIGH RISK]▼
Standalone other expenses +27.7% YoY vs revenue +12.7%; trade receivables up ~24% since March 2026 and standalone cash declined despite Rs 11,115 mn operating cash flow
- Apollo Hospitals/Governance and Leadership↓ [MEDIUM RISK]▼
Cessation of Dr. Madhu Sasidhar as President & CEO – Hospitals Division effective 14 Nov 2026, with support functions shifted to a PMO under the MD, during a period of multiple divestments (Cloudnine, ASPL/AFCPL)
- Sun Pharmaceutical/US Franchise Erosion↓ [HIGH RISK]▼
US sales -8.2% YoY on lenalidomide erosion; Ilumya growth slowed with management guiding to recovery 'over the next few quarters' and Q2 R&D of Rs 7,784 mn below intended levels; Assam ophthalmic plant halted after 11 product recalls
- Aurobindo Pharma/Emerging Market Softness↓ [MEDIUM RISK]▼
Growth Markets revenue -3.5% QoQ to Rs 1,026 cr and ARV +10.2% YoY; standalone other income -57.5% QoQ suggests headline PAT relies on operating performance that is not fully disclosed
- GSK Pharmaceuticals/Share Erosion [MEDIUM RISK]▼
Vaccine and general medicine brands lost unit share in Q2 FY27 (Fluarix -5.2%, Boostrix -3.6%, Calpol -3.0%), with EBITDA margin contracting 50 bps YoY on currency depreciation and input costs
- Zydus/Biocon Regulatory and Governance Watch↓ [LOW-MEDIUM RISK]▼
Zydus auditor rotation to Walker Chandiok & Co LLP and Biocon CTO transition effective 31 Dec 2026 / 1 Jan 2027 introduce operational transition risk; Dr. Reddy's responded to a BSE surveillance query on lenacapavir news, which the company judged not material
Opportunities (9)
- Aurobindo Pharma/Interim Dividend and Record Growth↓ (OPPORTUNITY)◆
Rs 7/share interim dividend (record date 11 Nov 2026, payment by 20 Nov) alongside record quarterly revenue and 21.0% EBITDA margin signals management confidence in cash generation
- Aurobindo Pharma/Lannett Integration↓ (OPPORTUNITY)◆
Lannett consolidated from 29 June 2026 is driving US growth ex-gRevlimid; if integration margins hold, FY27 H2 earnings could extend the 32.5% YoY PAT growth trajectory
- Zydus Lifesciences/Sterling Biotech API Acquisition↓ (OPPORTUNITY)◆
Completion of the Sterling Biotech API business acquisition on 2 Nov 2026, after the June 2026 Assertio deal, adds API vertical integration with a 29% consolidated revenue growth base
-
Net cash of Rs 33,490 mn and a 2026 board addition of an experienced independent director (Akhil Gupta) support governance; a stabilised margin profile would make current PAT depression a reversion candidate [OPPORTUNITY, CONDITIONAL]
- Biocon/Standalone and Generics Inflection↓ (OPPORTUNITY)◆
Standalone net profit for H1 more than doubled to Rs 1,439 mn and Generics EBITDA rose to Rs 64 cr from Rs 7 cr (margin up over 700 bps YoY); H2 guidance points to a stronger second half
- Sun Pharmaceutical/Organon Acquisition↓ (OPPORTUNITY)◆
Closing expected in Q4 FY27 with management indicating Ilumya growth recovery over the next few quarters; successful integration could re-rate the US franchise
- Glenmark/ISB 2001 Clinical Readout↓ (OPPORTUNITY)◆
ASH oral presentation on 12 Dec 2026 for the first-in-class CD38 x BCMA x CD3 trispecific in relapsed/refractory myeloma, partnered with AbbVie; positive data could validate royalty and milestone economics
- Apollo Hospitals/Digital Health Turnaround↓ (OPPORTUNITY)◆
Online PD & 24|7 EBITDA loss narrowed to Rs (127) mn from Rs (710) mn YoY and Digital health segment result +101% YoY, indicating operating leverage in the pharmacy-digital business
- Cipla/Global Operations Leadership Upgrade↓ (OPPORTUNITY)◆
Appointment of Vikram Janakiraman (ex-BCG MD and former Glenmark manufacturing leader) as Global Chief Technical Operating Officer effective 7 Dec 2026 strengthens operational and regulatory-inspection capability (USFDA, MHRA, ANVISA)
Sector Themes (6)
- Revenue Growth Decoupled from Profitability◆
Of the 11 in-scope listed companies with consolidated comparisons, most reported revenue growth but declining PAT or margins: Zydus (+29% revenue, -27% PAT), Lupin (+11% revenue, -22% PAT), Biocon (+2% revenue, -57% profit), while Aurobindo (+24% revenue, +33% PAT) was the notable exception; implication is that cost inflation (employee costs, finance costs, D&A) and acquisition accounting are absorbing top-line gains
- Margin Compression Across Generics and Biosimilars◆
EBITDA margin contraction is widespread: Zydus to 24.0% from 32.9% (-890 bps), Lupin to 25.1% from 31.3% (-620 bps EBITDA basis, ~770 bps on another basis), Biocon to 20% from 22%, GSK to 34% (-50 bps); average compression across the sector is roughly 300–400 bps, driven by US competition and loss of exclusivity
- US Market Erosion from Generics and LOE◆
US franchises are under pressure from competitive entry and LOE events: Lupin US sales -12.1% QoQ, Sun Pharma US sales -8.2% YoY on lenalidomide erosion, Zydus US still growing on ANDA approvals (12 approvals in Q2 FY27); investors should expect continued US pricing and volume pressure through FY27
- Acquisition-Led Growth and Balance-Sheet Strain◆
Several companies are funding growth through M&A: Lupin's Rs 20,397 mn of acquisition payments drove cash from Rs 41,677 mn to Rs 19,391 mn; Sun Pharma (Organon), Zydus (Sterling Biotech API, Assertio), and Aurobindo (Lannett) have each made material deals; consolidated comparisons are therefore not like-for-like and dilute organic growth reads
- Capital Returns Remain Steady◆
Dividends and capital allocation remain active: Aurobindo declared Rs 7/share interim (record date 11 Nov); Biocon's Rs 0.50 FY26 final dividend is being withheld pending KYC/bank data updates; Lupin paid Rs 8,230 mn of dividends in H1 FY27, showing that shareholder payouts continue even as margins compress
- Leadership and Governance Transitions◆
Multiple leadership changes are underway: Apollo's Hospitals Division CEO exit (14 Nov), Biocon's CTO transition (31 Dec/1 Jan), Cipla's new Global CTO (7 Dec), Lupin's independent director appointment, and Zydus's statutory auditor change to Walker Chandiok & Co LLP; these clustered changes deserve monitoring as operating and governance signals
Watch List (8)
-
Board meeting and results on 12 Nov 2026 with investor call 4:30–5:30 pm IST hosted by Motilal Oswal; key to read whether Alkem's domestic and export mix is holding margins as peers compress
-
Interim dividend record date 11 Nov 2026 and payment by 20 Nov 2026; watch for Lannett integration commentary and Growth Markets recovery from the 3.5% QoQ decline on the 5 Nov earnings call
-
Acquisition expected to close in Q4 FY27; watch for R&D catch-up in H2 (Q2 spend Rs 7,784 mn below plan), Ilumya recovery trajectory, and the Assam ophthalmic plant restart after the 11 product recalls
-
Monitor the Rs 3,163 mn antitrust settlement impact, the Rs 769 mn subsidiary impairment, and whether US sales stabilise after the 12.1% QoQ decline in Q2 FY27
-
Dr. Madhu Sasidhar's exit effective 14 Nov 2026 and PMO reporting change under the MD; watch for successor appointment and whether standalone other expense growth (+27.7%) moderates
-
ISB 2001 (ABBV-2001) oral presentation at the 68th ASH Annual Meeting on 12 Dec 2026, 4:00–4:15 pm CST; updated Phase 1 TRIgnite-1 data will inform AbbVie partnership value
-
Management characterised FY27 as a transition year with stronger H2; track Biosimilars revenue recognition timing and the CTO handover (Dr. Ghatnekar exits 31 Dec 2026, Mukesh Rathi from 1 Jan 2027); withheld FY26 final dividend (Rs 0.50/share) should be resolved via KYC updates
-
Shareholder approval of Walker Chandiok & Co LLP at the 32nd AGM; watch for Medical Technologies loss trajectory (Rs (928) mn in Q2) and the Q2 sequential revenue dip (-1.3% QoQ) during integration of Sterling Biotech API and Assertio
Filing Analyses
(44)
04-11-2026
Zydus Lifesciences filed its Q2 FY27 earnings investor presentation on November 4, 2026, covering the quarter ended September 30, 2026. Total revenues rose 29% YoY to Rs 79,096 mn, with EBITDA of Rs 18,945 mn (24.0% margin) and reported PAT of Rs 9,255 mn, up 26.6% YoY, though EBITDA margin declined from 32.9% a year earlier and PAT grew more slowly than revenue. Net debt stood at Rs 51,998 mn, and organic capex for the quarter was Rs 4,655 mn.
- · USFDA inspections at SEZ II Ahmedabad (one observation) and Moraiya formulations facility (five observations) concluded
- · Transdermal product approval received for Moraiya site on October 21, 2026
- · Company received 12 ANDA approvals and filed 4 ANDAs in Q2 FY27; 5 new US products launched
- · Secondary sales growth in India was 20% YoY, with chronic and sub-chronic share at 56.9%
- · Net debt to EBITDA improved to 0.68x from 0.28x-range history as shown in trend chart, and net working capital rose to Rs 86,143 mn (Q2 FY26 comparison) versus Rs 75,938 mn in Q2 FY27
- · Consumer Wellness QoQ decline of 21.5% reflects sequential softness despite strong YoY growth
- · ESG rating reached 71/100 (Leader category, top 10%), with core ESG rating at 68/100 from 66/100
04-11-2026
Apollo Hospitals reported consolidated revenue from operations of ₹76,149 Million (₹7,614.9 Cr) for Q2 FY27 (three months ended September 30, 2026), up from ₹61,868 Million in the corresponding quarter of the prior year (+23.1% YoY), and consolidated profit after tax of ₹6,595 Million, up from ₹4,940 Million (+33.5% YoY). Standalone revenue from operations rose to ₹26,561 Million from ₹23,561 Million (+12.7% YoY), and standalone PAT was ₹4,757 Million versus ₹4,199 Million (+13.3% YoY). Performance was mixed: standalone EBITDA margin and the discontinued pharmacy/retail-diagnostics divestment (ASPL/AFCPL) weighed on certain comparisons, and the Company also disclosed the cessation of Dr. Madhu Sasidhar as President & CEO – Hospitals Division effective November 14, 2026.
- · Consolidated EBITDA-type segment results: Healthcare services segment result rose to ₹7,600 Mn from ₹6,319 Mn (+20.3% YoY), while Digital health & pharmacy distribution segment result increased to ₹1,728 Mn from ₹859 Mn (+101.2% YoY).
- · Retail health & diagnostics segment result was ₹380 Mn versus ₹108 Mn a year earlier, but segment revenue was only ₹4,293 Mn, and a separate Retail health & diagnostics discontinued operations line item carries ₹5,306 Mn of assets held for sale against ₹7,049 Mn of associated liabilities.
- · Standalone other expenses rose to ₹9,203 Mn from ₹7,208 Mn (+27.7% YoY), outpacing standalone revenue growth of 12.7%.
- · Consolidated net cash from operating activities for six months rose to ₹14,933 Mn from ₹13,253 Mn (+12.7%), while standalone net cash from operating activities was ₹11,115 Mn versus ₹9,438 Mn.
- · Consolidated borrowings (current and non-current) totalled approximately ₹55,948 Mn, and consolidated trade receivables increased to ₹42,562 Mn from ₹34,849 Mn at March 31, 2026 (+22.1%), a rise that outpaced revenue growth on a sequential basis.
- · Consolidated discontinued operations (ASPL/AFCPL) recorded a profit before tax of ₹49 Mn in Q2 FY27, against a loss of ₹(66) Mn in Q2 FY26, and the divestment was completed on October 12, 2026 after CCI approval on September 1, 2026.
- · Labour Code implementation resulted in an exceptional item of ₹114 Mn (standalone) and ₹192 Mn (consolidated) for the year ended March 31, 2026, presented as non-recurring.
- · A Karnataka Revenue Department cancellation order on land grant conditions for subsidiary Imperial Hospitals & Research Centre Limited is under challenge; the High Court granted an interim stay on April 10, 2026, and the auditor's conclusion is not modified for this matter (emphasis of matter).
- · Deloitte Haskins & Sells LLP issued an unmodified review conclusion on both standalone and consolidated results, with reliance placed on other auditors' reviews for 28 subsidiaries and 1 joint venture plus 5 associates (consolidated), and 9 unreviewed subsidiaries.
- · Standalone basic EPS for Q2 FY27 was ₹33.08 versus ₹29.20 in Q2 FY26 (+13.3%), while the six-month standalone EPS was ₹59.86 versus ₹50.55 a year earlier.
- · Dr. Madhu Sasidhar's cessation as President & CEO – Hospitals Division takes effect after the close of business on November 14, 2026, and Dr. Ritu Garg, Anand Wasker and Dr. N. Venkatesan were designated Senior Management Personnel effective November 4, 2026.
04-11-2026
Apollo Hospitals Enterprise Limited reported standalone revenue from operations of ₹26,561 Mn in Q2 FY27 (quarter ended September 30, 2026), up 12.7% YoY from ₹23,561 Mn, while standalone PAT rose 13.3% YoY to ₹4,757 Mn. Consolidated revenue from operations grew 23.1% YoY to ₹76,149 Mn and consolidated PAT attributable to owners rose 32.0% YoY to ₹6,299 Mn, with mixed signals in the balance sheet: consolidated trade receivables increased to ₹42,562 Mn from ₹34,849 Mn at March 31, 2026, and standalone profit before tax growth (+12.3%) trailed the strong consolidated revenue expansion.
- · Consolidated results include discontinued operations (Apollo Specialty Hospitals and Apollo Fertility Centre), with discontinued operations contributing a loss of ₹90 Mn in Q1 FY27 and a profit of ₹49 Mn in Q2 FY27.
- · Exceptional item of ₹114 Mn (standalone) and ₹192 Mn (consolidated) relating to increased gratuity and leave liabilities under the Labour Codes effective November 21, 2025 was recognised in the prior year period.
- · Standalone net cash from operating activities rose to ₹11,115 Mn for H1 FY27 from ₹9,438 Mn, while consolidated capex on PP&E and intangibles increased to ₹11,999 Mn from ₹7,065 Mn.
- · Consolidated borrowings stood at ₹24,487 Mn non-current and ₹31,461 Mn current at September 30, 2026, versus ₹24,301 Mn and ₹32,284 Mn at March 31, 2026.
- · A Karnataka High Court matter relating to land allotment to subsidiary Imperial Hospitals & Research Centre Limited remains pending, with an interim stay granted on April 10, 2026; the auditor flagged it without modifying its conclusion.
- · Dr. Madhu Sasidhar ceases as President & CEO - Hospitals Division effective close of business November 14, 2026; Dr. Ritu Garg, Anand Wasker and Dr. N. Venkatesan are designated Senior Management Personnel from November 4, 2026.
04-11-2026
Apollo Hospitals reported standalone unaudited results for the quarter and half year ended 30 September 2026, with Q2 FY27 revenue from operations of ₹26,561 Million (vs ₹23,561 Million in Q2 FY26 per the table, a 12.7% YoY rise) and six-month revenue of ₹55,590 Million (up 22.9% YoY from ₹45,240 Million). Profit after tax for the half year rose 18.4% to ₹8,607 Million, but quarterly PAT declined 9.1% sequentially from ₹4,199 Million to ₹4,757 Million in Q2, while the sequential Q2 PAT increase versus Q1 (₹3,852 Million) was strong. The Board also announced CEO-level leadership changes and completion of the Cloudnine (KCIL) divestment on 3 November 2026.
- · Dr. Madhu Sasidhar ceases as President & CEO - Hospitals Division and SMP effective close of business 14 November 2026
- · Support functions and other regions previously reporting to the President & CEO now report to the Project Management Office under the Managing Director
- · Q2 FY27 PAT declined sequentially from ₹3,852 Mn? No: Q1 FY27 PAT was ₹3,852 Mn, so Q2 PAT rose sequentially by 23.5%
- · Q2 FY27 standalone EBITDA of ₹7,226 Mn, up 21.9% YoY from ₹5,929 Mn
- · Trade receivables rose to ₹10,493 Mn from ₹8,473 Mn at 31 Mar 2026 (+23.8%), and operating cash flow was ₹11,115 Mn (+17.8% YoY)
- · Capex (purchase of PP&E, CWIP and intangibles) rose to ₹6,655 Mn in H1 FY27 from ₹3,422 Mn in H1 FY26, nearly doubling
- · Divestment of ASHPL and AFCPL to KCIL closed on 3 November 2026; both have ceased to be subsidiaries of AHLL
04-11-2026
Aurobindo Pharma filed the investor/analyst presentation for its Q2FY27 and H1FY27 unaudited results call scheduled for November 5, 2026. The quarter delivered record revenue of ₹10,263 Cr (up 23.9% YoY and 12.2% QoQ) and record EBITDA of ₹2,156 Cr at a 21.0% margin, with PAT of ₹1,124 Cr (up 32.5% YoY). Performance was not uniformly strong: Growth Markets revenue declined 3.5% QoQ to ₹1,026 Cr, ARV grew only 10.2% YoY, and Non Beta-lactam API rose 11.3% YoY against a sharper sequential jump, while US revenue ex-gRevlimid growth and the Lannett acquisition drove much of the expansion.
- · Growth Markets revenue declined 3.5% QoQ to ₹1,026 Cr, a flat-to-negative sequential trend not highlighted in the headline results
- · ARV revenue grew only 10.2% YoY to ₹359 Cr, the slowest growth among major segments aside from Non Beta-lactam API
- · Non Beta-lactam API grew 11.3% YoY to ₹304 Cr, lagging Beta-lactam API growth of 24.8% YoY
- · Other income fell 21.9% QoQ to ₹165 Cr and forex gain fell 94.6% QoQ, indicating a lower non-operating contribution to PBT
- · Share of JV profit turned to a loss of ₹3 Cr in Q2FY27 versus a ₹2 Cr profit in Q2FY26
- · Net debt/(net cash) moved to US$ (189) Mn net cash including investments versus US$ (317) Mn at Mar-26 Apparent decline in cash balances in INR terms (₹10,044 Cr at Sep-26 versus ₹10,676 Cr at Mar-26)
- · Gross debt rose to ₹8,232 Cr at Sep-26 from ₹7,673 Cr at Mar-26, driven by FX-denominated loans restated at a weaker rupee
- · Revenue ex-gRevlimid growth of 20% QoQ is driven partly by Lannett integration, so organic growth is less clear
- · Biosimilar commercial traction remains early: four products launched, while several pipeline milestones (FDA filings, pertuzumab Phase 1, anti-HER2 clinical entry) are targeted for future periods
- · Eight-quarter and multi-period comparisons show revenue has grown steadily but QoQ EBITDA margin expansion is partly offset by overheads rising 13.2% QoQ
04-11-2026
Aurobindo Pharma's board approved a proposal to file a Scheme of Amalgamation with NCLT Hyderabad merging wholly owned subsidiary Auroactive Pharma Private Limited (transferor) into Apitoria Pharma Private Limited (transferee), both engaged in API manufacturing. The stated rationale is consolidating API businesses, improving operational efficiency and capacity utilisation of the Auroactive facility, and simplifying group structure. The parent company is not a party to the scheme and its shareholding is unchanged.
- · Share exchange ratio: 97 equity shares of Apitoria Pharma (INR 10 face value) issued for every 10,000 equity shares of Auroactive Pharma, resulting in 23,95,900 new shares
- · Auroactive Pharma was incorporated January 9, 2020; Apitoria Pharma was incorporated December 20, 2017
- · Transaction is stated to be at arm's length based on an independent registered valuer's report
- · Filing states the transaction is exempt from SEBI LODR Regulations 23(2)-(4) and not subject to Section 188 of the Companies Act, 2013 per MCA Circular 30/2014
- · Auroactive Pharma's turnover (₹701.3 million) is roughly 1.1% of Apitoria Pharma's (₹64,430.8 million), indicating a small target relative to the transferee
04-11-2026
Lupin Limited reported standalone and consolidated unaudited results for the quarter and six months ended September 30, 2026. Standalone Q2 FY27 total revenue from operations was ₹35,673.4 million, down from ₹40,682.8 million in the year-ago quarter (-12.3%), and standalone net profit after tax was a loss of ₹59.1 million versus a profit of ₹13,573.5 million a year earlier, largely reflecting an exceptional charge of ₹769.3 million for diminution in a subsidiary investment. Consolidated Q2 FY27 revenue from operations rose to ₹78,272.6 million from ₹70,475.1 million (+11.1% YoY), but consolidated PAT fell to ₹11,553.0 million from ₹14,848.3 million (-22.2% YoY), with consolidated EPS (basic) at ₹25.27 versus ₹32.36 a year ago.
- · Standalone profit before exceptional items and tax was ₹811.2 Mn in Q2 FY27, against ₹10,431.3 Mn a year earlier, while a ₹769.3 Mn exceptional charge (investment diminution in a subsidiary) pushed standalone pre-tax profit to ₹41.9 Mn.
- · Consolidated Q2 FY27 profit before tax rose to ₹15,796.0 Mn from ₹20,069.7 Mn a year earlier (-21.3% YoY), with the consolidated tax expense rising to ₹4,243.0 Mn from ₹5,221.4 Mn.
- · Consolidated cash and cash equivalents fell to ₹19,390.7 Mn at September 30, 2026 from ₹41,677.3 Mn at March 31, 2026, reflecting ₹20,397.3 Mn of business acquisition payments and ₹8,230.2 Mn of dividend payments in the six months.
- · Consolidated goodwill rose to ₹33,679.9 Mn from ₹26,585.3 Mn, and other intangible assets rose to ₹41,762.9 Mn from ₹28,862.5 Mn, following the VISUfarma acquisition.
- · Consolidated non-controlling interest fell to ₹6.9 Mn from ₹651.0 Mn after Nanomi B.V. acquired additional stake in Multicare Pharmaceuticals Philippines Inc. for ₹3,701.2 Mn.
- · A further ₹1,323.1 Mn antitrust provision was recorded in Q4 FY26, and a ₹3,162.8 Mn settlement was paid in the six months ended September 30, 2026, leaving a remaining provision for future antitrust settlements.
- · Consolidated Q2 FY27 other comprehensive income was ₹303.5 Mn versus ₹958.2 Mn a year earlier, a decline that narrowed total comprehensive income growth.
- · Auditors (Deloitte Haskins & Sells) issued a limited review report with no modification to conclusions for both standalone and consolidated results.
04-11-2026
Lupin Limited reported standalone and consolidated unaudited results for the quarter and six months ended September 30, 2026. Consolidated revenue from operations rose to ₹78,272.6 million for Q2 FY27 versus ₹70,475.1 million in the year-ago quarter (+11.1% YoY), while consolidated net profit after tax fell to ₹11,553.0 million from ₹14,848.3 million (-22.2% YoY), with exceptional items and a sharp rise in deferred tax weighing on earnings. Standalone revenue from operations was ₹35,673.4 million in Q2, while standalone net profit swung to a loss of ₹(59.1) million versus ₹13,573.5 million a year earlier, reflecting a ₹3,162.8 million antitrust settlement and a ₹769.3 million investment impairment in a subsidiary.
- · Consolidated Profit before tax fell to ₹15,796.0 million from ₹20,069.7 million YoY (-21.3%), and consolidated deferred tax expense rose to ₹3,521.8 million from ₹1,981.5 million
- · Standalone Profit before exceptional item and tax was ₹811.2 million versus ₹10,431.3 million a year earlier, and standalone results include a ₹5,926.8 million exceptional gain in the prior-year quarter
- · Consolidated cash and cash equivalents declined to ₹19,390.7 million from ₹41,677.3 million at March 31, 2026, largely reflecting acquisition payments of ₹20,397.3 million in the six months
- · Consolidated goodwill rose to ₹33,679.9 million from ₹26,585.3 million following the VISUfarma acquisition effective April 1, 2026 (total consideration ₹20,902.7 million)
- · Consolidated Basic EPS after exceptional items was ₹25.27 for the quarter, versus ₹32.36 a year ago
04-11-2026
Lupin Limited's Board, at its November 03, 2026 meeting, unanimously approved the appointment of Mr. Akhil Gupta (DIN: 00028728) as an Additional Director (Non-Executive, Independent), effective November 03, 2026, and as an Independent Director for a five-year term running to November 02, 2031, subject to shareholder approval. The filing confirms Mr. Gupta is not debarred from directorship and is not related to any current director, KMP, or promoter. This is a board governance change with no reported financial impact.
- · Mr. Gupta is a qualified Chartered Accountant with over four decades of experience and an Advanced Management Program credential from Harvard Business School
- · He is President of the Telecom Sector Skill Council and a member of the CII Task Force on Insolvency and Bankruptcy, and previously served on the Insolvency and Bankruptcy Board of India's advisory committee
- · Former Vice Chairman of Bharti Enterprises, where he contributed to organic growth and acquisitions
- · Recognized with awards including the EY Entrepreneur of the Year, CNBC-TV18 Best CFO Awards, and induction into the CFO India Hall of Fame
- · Board meeting commenced November 03, 2026 at 7:30 p.m. IST and concluded November 04, 2026 at 12:25 a.m. IST
- · Appointment is subject to approval of Members (shareholders) of the Company
04-11-2026
Lupin Limited filed its Q2 FY27 investor presentation (quarter and half year ended September 30, 2026). Q2 FY27 net sales rose 14.0% YoY to INR 77,855 mn, but fell 5.3% QoQ from INR 82,172 mn, and EBITDA declined 8.4% YoY and 20.5% QoQ to INR 19,574 mn (25.1% margin vs 31.3% a year ago). Net income fell 21.8% YoY to INR 11,553 mn, with the company citing increased US competition and loss of exclusivity on key products as headwinds.
- · US sales declined sharply QoQ from INR 30,202 mn to lower levels amid increased competition and loss of exclusivity (LOE) on key products; management cites seasonal demand and volume growth in select products as partial offsets
- · Q2 FY27 EBITDA margin compressed to 25.1% from 31.3% a year ago and 30.0% in Q1 FY27
- · H1 FY27 net income fell 4.7% YoY despite 23.1% sales growth, reflecting margin pressure
- · Other operating income fell 80.7% YoY to INR 418 mn
- · Sugammadex 505(b)(2) injection launched in the US; Apixaban Oral Suspension received tentative FDA approval
- · Site compliance: Ankleshwar and Somerset received EIR/VAI status; Mandideep Unit I received WHO approval; Pithampur Unit II remains under OAI with remediation in progress
- · India business grew 14.7% YoY, with anti-diabetes growing 28.6% in H1 vs IPM growth of 18.8%
- · Continued cost optimization initiatives cited to improve profitability
- · Net debt to equity ratio at (0.15) in Q2 FY27, indicating net cash position
04-11-2026
Lupin Limited reported Q2 FY2027 consolidated revenue (sales) of INR 77,855 Mn, up 14.0% YoY but down 5.3% QoQ. However, profitability weakened sharply: EBITDA fell 10.7% YoY to INR 21,712 Mn with margin compressing 770 bps to 27.9%, PBT declined 21.3% YoY to INR 15,796 Mn, and PAT dropped 22.2% YoY to INR 11,553 Mn. Growth was mixed across markets, with Emerging Markets declining 3.5% YoY.
- · Net debt stood at INR -33,490 Mn (net cash position) as on September 30, 2026, with net debt to equity at -0.14
- · Emerging Markets sales fell 10.0% QoQ and U.S. sales fell 12.1% QoQ, indicating sequential softness across major markets
- · Employee cost rose 28.8% YoY to INR 14,236 Mn (18.3% of sales) and Manufacturing & other expenses rose 23.2% YoY, outpacing sales growth
- · Depreciation, amortization & impairment rose 53.4% YoY to INR 4,859 Mn, and Forex gain shrank from INR 2,038 Mn to INR 870 Mn, both weighing on profitability
- · Operating working capital was INR 75,420 Mn with operating days at 87 for the quarter
- · Company is 3rd largest U.S. generic and total pharma player by prescriptions (IQVIA Sept 2026) and 8th largest in Indian pharma (IQVIA MAT Sept 2026)
04-11-2026
Zydus Lifesciences reported standalone revenue from operations of INR 34,820 Million for Q2 FY27 (quarter ended September 30, 2026), up 21.3% YoY from INR 28,712 Million, while net profit fell 38.2% YoY to INR 7,145 Million from INR 11,566 Million, largely because other income dropped sharply (dividends from subsidiaries fell to INR 220 Million from INR 4,198 Million). Consolidated revenue from operations rose 29.3% YoY to INR 79,096 Million, but consolidated net profit attributable to owners declined 26.6% YoY to INR 9,255 Million from INR 12,609 Million, with segment profit before tax and joint ventures down in Pharmaceuticals and Medical Technologies losses widening. The company also completed the acquisition of the API business of Sterling Biotech Limited on November 2, 2026, following the June 2026 Assertio Holdings acquisition.
- · Standalone other income fell to INR 1,646 Mn from INR 5,415 Mn YoY, driven by lower subsidiary dividends, which materially reduced standalone PAT growth.
- · Consolidated Pharmaceuticals segment profit before tax fell to INR 13,186 Mn from INR 17,749 Mn YoY, while Medical Technologies segment loss widened to INR (928) Mn from INR (345) Mn.
- · Consolidated employee benefits expense rose to INR 13,571 Mn from INR 10,342 Mn YoY and finance costs rose to INR 1,870 Mn from INR 1,013 Mn YoY.
- · Standalone cash and cash equivalents declined to INR 1,680 Mn from INR 3,270 Mn at March 31, 2026, and standalone net cash used in investing activities was INR (211) Mn for the half year versus cash generation of INR 15,736 Mn in the prior-year half.
- · Consolidated total liabilities rose to INR 252,841 Mn from INR 189,054 Mn YoY, and consolidated borrowings increased to INR 132,496 Mn from INR 117,000 Mn at March 31, 2026 (current plus non-current).
- · Auditor's review report contains an emphasis of matter-style limitation: 59 subsidiaries (total assets INR 464,392 Mn) were reviewed by other auditors and 37 subsidiaries plus 4 joint ventures were unreviewed, though the auditor did not modify its conclusion.
- · Consolidated EPS basic and diluted was INR 9.28 for Q2 FY27 versus INR 12.53 in Q2 FY26.
04-11-2026
Zydus Lifesciences reported standalone and consolidated unaudited results for Q2 FY27 (quarter ended September 30, 2026). Consolidated revenue from operations rose to INR 79,096 Million in the quarter, up from INR 61,232 Million a year earlier (about +29% YoY), but declined sequentially from INR 80,170 Million in Q1, and consolidated net profit fell to INR 9,255 Million from INR 12,609 Million (about -27% YoY) amid higher employee, depreciation and finance costs. Standalone PAT was INR 7,145 Million versus INR 11,566 Million a year ago, reflecting lower dividend income from subsidiaries; the company also completed the acquisition of the API business of Sterling Biotech on November 2, 2026.
- · Consolidated EBITDA-type operating profit before JV share, exceptional items and tax fell to INR 12,329 Million from INR 17,232 Million a year earlier, with pharmaceuticals segment results down to INR 13,186 Million from INR 17,749 Million.
- · Medical technologies segment posted a loss of INR (928) Million in the quarter versus INR (345) Million a year earlier.
- · Standalone dividend income from subsidiaries dropped to INR 220 Million from INR 4,198 Million, a key driver of lower standalone profit.
- · Consolidated total liabilities rose to INR 252,841 Million from INR 189,054 Million a year earlier, with Pharmaceuticals liabilities up substantially.
- · Net cash from operating activities for the half year rose to INR 31,623 Million from INR 12,207 Million, while the auditor's review report notes unreviewed subsidiary and JV information but no modification of conclusion.
- · Provision of INR 396 Million for torrential-rain damage at Ahmedabad facilities, with insurance receivable of INR 376 Million recognised.
04-11-2026
Zydus Lifesciences Limited's Board approved, on November 4, 2026, the appointment of Walker Chandiok & Co LLP (a Grant Thornton International member firm) as statutory auditors for a first five-year term, from the conclusion of the 32nd AGM for FY2026-27 through the 37th AGM for FY2031-32, replacing Deloitte Haskins & Sells LLP, whose second consecutive five-year term ends at that AGM under the mandatory rotation requirement of Section 139(2) of the Companies Act, 2013. The appointment is subject to shareholder approval at the 32nd AGM.
- · Walker Chandiok & Co LLP was established in 1935, is over 90 years old, and holds a valid peer review certificate
- · Walker Chandiok & Co LLP has significant experience auditing large pharmaceutical and healthcare companies, supported by audit, tax, technology and industry specialist teams
- · Walker Chandiok & Co LLP audits several large companies, including some of the top 100 listed entities in India
- · Board meeting held on November 4, 2026 (commenced 10:50 a.m., concluded 12:10 p.m.)
- · No disclosable relationship between directors and the proposed auditor
04-11-2026
Zydus Lifesciences reported unaudited consolidated results for Q2 and H1 FY27 (quarter/half year ended September 30, 2026). Revenue from operations grew 29.2% y-o-y to Rs. 79,096 mn in Q2 and 25.4% to Rs. 1,59,266 mn in H1, driven by Consumer Wellness (+76.1%), North America formulations (+20.8%) and International Markets (+33.6%). However, profitability declined sharply: Q2 EBITDA fell 6.0% y-o-y to Rs. 18,945 mn (margin 24.0% vs 32.9%), PBT fell 25.5% and Net Profit fell 26.6% to Rs. 9,255 mn; H1 Net Profit fell 30.9% to Rs. 18,859 mn.
- · Q2 FY27 PBT fell 25.5% y-o-y to Rs. 12,617 mn; H1 FY27 PBT fell 27.9% to Rs. 26,308 mn
- · Q2 FY27 revenue declined 1.3% q-o-q and Q2 net profit declined 3.6% q-o-q, indicating sequential softness
- · Consumer Wellness revenue fell 21.5% q-o-q and MedTech revenue fell 20.6% q-o-q in Q2
- · Q2 FY27 APIs revenue was essentially flat y-o-y (+0.9%) and fell 17.7% q-o-q
- · Q2 FY27 R&D spend was Rs. 6,573 mn (8.3% of revenue); H1 R&D was Rs. 12,997 mn (8.2%)
- · Net debt to equity 0.19x and net debt to EBITDA 0.62x as on September 30, 2026
- · Two USFDA inspections concluded at SEZ II Ahmedabad (one observation) and Moraiya (five observations); company working to address them
- · USFDA accepted for review the BLA for FYB206, described as the first publicly announced Keytruda biosimilar filing accepted in the US
- · Q2 North America generics: 4 ANDAs filed, 12 approvals (including 2 tentative), 5 launches
- · Earnings call scheduled at 3:30 p.m. IST on November 4, 2026
04-11-2026
Biocon Limited reported unaudited consolidated results for the quarter and half year ended September 30, 2026. Q2 FY27 consolidated revenue from operations was Rs. 43,889 Million, up 2.2% QoQ from Rs. 43,360 Million and up 2.2% YoY from Rs. 42,955 Million, while profit for the period fell to Rs. 567 Million from Rs. 1,368 Million in the previous quarter (down 58.6%) and from Rs. 1,328 Million a year ago (down 57.3%). Total comprehensive income turned negative at Rs. (1,382) Million, reflecting a sharp swing in other comprehensive income. Mixed performance: Services revenue declined 8.6% YoY to Rs. 8,138 Million (segment profit fell to Rs. 537 Million from Rs. 852 Million), while Biosimilars segment profit plunged to Rs. 325 Million from Rs. 1,672 Million a year earlier, and the Generics segment remained loss-making at Rs. (304) Million.
- · Consolidated Biosimilars segment profit before tax fell to Rs. 325 Mn in Q2 FY27 from Rs. 1,714 Mn in Q1 FY27 and Rs. 1,672 Mn in Q2 FY26.
- · Consolidated Generics segment remained loss-making at Rs. (304) Mn in Q2 FY27, versus Rs. (692) Mn a year earlier, an improvement but still negative.
- · Consolidated Services revenue declined 8.6% YoY to Rs. 8,138 Mn, while Services segment profit fell to Rs. 537 Mn from Rs. 852 Mn.
- · Consolidated other comprehensive loss of Rs. (6,012) Mn on items not reclassified to profit or loss drove the negative total comprehensive income.
- · Consolidated exceptional items were Rs. (67) Mn in Q2 FY27 (termination benefits), down from Rs. (119) Mn in Q2 FY26.
- · Consolidated net debt-related finance costs eased to Rs. 2,401 Mn in Q2 FY27 from Rs. 2,722 Mn in Q2 FY26.
- · Consolidated cash and cash equivalents stood at Rs. 22,039 Mn at September 30, 2026, versus Rs. 24,165 Mn at March 31, 2026.
- · Standalone interim dividend context: final dividend of Rs. 0.50 per share was approved at the August 06, 2026 AGM.
- · BBL became a wholly owned subsidiary of Biocon Limited effective June 29, 2026 following a share swap transaction.
04-11-2026
Biocon Limited reported unaudited consolidated results for the quarter and half year ended September 30, 2026. Consolidated revenue from operations for Q2 FY27 was Rs. 43,889 million, up 2.2% YoY from Rs. 42,955 million, while consolidated profit for the period fell 57% YoY to Rs. 567 million from Rs. 1,328 million, and attributable profit to shareholders was Rs. 413 million versus Rs. 845 million. Standalone revenue from operations rose 8.1% YoY to Rs. 6,305 million, but standalone profit for the quarter rose 29.4% YoY to Rs. 917 million, with exceptional items and restructuring costs continuing to weigh on reported earnings.
- · Consolidated Biosimilars segment PBT fell to Rs. 325 Mn in Q2 FY27 from Rs. 1,672 Mn in Q2 FY26, while Generics losses narrowed to Rs. (304) Mn from Rs. (692) Mn.
- · Consolidated Services segment PBT fell to Rs. 537 Mn in Q2 FY27 from Rs. 852 Mn in Q2 FY26, and was negative in Q1 FY27 at Rs. (57) Mn.
- · Consolidated exceptional items were Rs. (67) Mn in Q2 FY27 (termination benefits) versus Rs. (119) Mn in Q2 FY26.
- · Consolidated Employee benefits expense was Rs. 8,919 Mn in Q2 FY27 versus Rs. 8,982 Mn in Q2 FY26; Depreciation and amortisation rose to Rs. 5,638 Mn from Rs. 4,730 Mn (up 19.2%).
- · Consolidated Finance costs fell to Rs. 2,401 Mn in Q2 FY27 from Rs. 2,722 Mn in Q2 FY26 (down 11.8%).
- · Consolidated Other comprehensive income was negative Rs. (1,949) Mn in Q2 FY27, reducing total comprehensive income to Rs. (1,382) Mn, versus Rs. 11,026 Mn in Q2 FY26.
- · Consolidated Cash and cash equivalents fell to Rs. 22,039 Mn at September 30, 2026 from Rs. 24,165 Mn at March 31, 2026; net cash flow from operations for H1 was Rs. 7,690 Mn versus Rs. 8,034 Mn in H1 FY26.
- · Consolidated Total borrowings (non-current plus current) rose to approximately Rs. 1,51,101 Mn from Rs. 1,48,247 Mn at March 31, 2026.
- · Consolidated Non-controlling interests declined to Rs. 23,132 Mn from Rs. 25,897 Mn at March 31, 2026, reflecting BBL becoming wholly owned from June 29, 2026.
- · Standalone Investments rose to Rs. 2,53,229 Mn from Rs. 2,48,056 Mn at March 31, 2026, while standalone Cash and cash equivalents fell to Rs. 481 Mn from Rs. 914 Mn.
- · Standalone Net cash flow from operating activities was negative Rs. (93) Mn in H1 FY27 versus Rs. 1,350 Mn in H1 FY26, while Purchase of treasury shares was Rs. 996 Mn.
- · Standalone Paid-up equity share capital increased to Rs. 8,148 Mn from Rs. 8,105 Mn following the June 29, 2026 preferential allotment of 87,86,362 shares for the BBL share swap at Rs. 376.41 per share.
- · Auditor's review reports are unqualified; S.R. Batliboi & Associates LLP's consolidated review relies on another auditor's report for a foreign subsidiary with total assets of Rs. 57,569 Mn and Q2 total revenue of Rs. 5,609 Mn.
04-11-2026
Biocon reported consolidated un-audited results for Q2FY27 (quarter ended September 30, 2026), with total income of Rs 4,423 Cr (+1% YoY), revenue from operations of Rs 4,389 crore (+2% YoY), and EBITDA of Rs 865 Cr (-7% YoY). Biopharma revenue rose 5% YoY to Rs 3,583 crore, but Services revenue fell 9% YoY to Rs 833 crore and EBITDA margin contracted to 20% from 22%. Reported net profit was Rs 41 Cr, down 52% YoY from Rs 85 Cr, while H1FY27 net profit rose 57% YoY to Rs 182 crore on a lower base.
- · Q2FY27 Services revenue declined 9% YoY, offset by 13% sequential growth, with Syngene reporting a 9% YoY revenue decline due to lower Zoetis revenues and forex hedge losses
- · Other income fell 63% YoY to Rs 34 crore, a major contributor to the flat total income growth
- · Depreciation and amortisation rose 19% YoY to Rs 563 crore, weighing on profitability
- · PBT before exceptional items fell 66% YoY to Rs 62 crore
- · Secured a ~USD 400 million 10-year Pertuzumab PDP partnership in Brazil and over USD 100 million in new US contracts
- · Pebrilzo (biosimilar Pertuzumab) received a positive CHMP opinion and earliest licensed launch dates across EU, UK, US and RoW under a Genentech settlement
04-11-2026
Biocon Limited's Board approved unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026, and announced a senior management change: CTO Dr. Mandar Shrikant Ghatnekar resigns effective close of business December 31, 2026, with Mr. Mukesh Rathi appointed CTO effective January 01, 2027. Standalone revenue from operations rose 0.9% QoQ to ₹6305 million in Q2 FY27 and 8.1% YoY versus ₹5833 million, but standalone profit after tax of ₹917 million in the quarter was 29% higher YoY, while standalone net profit for the half-year grew to ₹1439 million from ₹626 million, aided by lower finance costs and a weaker comparative base. Consolidated revenue from operations rose 1.2% YoY to ₹43889 million for the quarter, yet consolidated profit for the period declined 57% YoY to ₹567 million, with profit before exceptional items and tax falling from ₹1832 million to ₹615 million.
- · Consolidated profit for the half-year ended Sep 30, 2026 was ₹1935 Million versus ₹2220 Million in the prior-year half, a 12.8% decline.
- · Standalone exceptional items were nil in H1 FY27, while the comparative period reflected material exceptional charges; consolidated exceptional items were ₹202 Million for the half-year versus ₹291 Million prior year.
- · Consolidated sale of services revenue fell 7.3% YoY in Q2 FY27 to ₹8138 Million, while sale of products rose 4.3% YoY to ₹35312 Million.
- · Consolidated finance costs fell to ₹2401 Million in Q2 FY27 from ₹2722 Million a year earlier, a 11.8% decline.
- · Standalone preference of Q2 FY27 finance costs fell sharply to ₹219 Million from ₹672 Million in Q2 FY26.
04-11-2026
Alkem Laboratories Limited has notified the stock exchanges that its Board of Directors will meet on Thursday, 12 November 2026 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2026. The notice is a routine intimation under Regulation 29 read with Regulation 33 of the SEBI LODR Regulations and contains no financial figures or performance data.
- · Board meeting date: Thursday, 12 November 2026
- · Agenda: approval of standalone and consolidated unaudited financial results for quarter and half year ended 30 September 2026
- · Scrip code 539523, symbol ALKEM
04-11-2026
Alkem Laboratories Limited has scheduled a conference call on Thursday, November 12, 2026, from 4:30 pm to 5:30 pm IST to discuss its Q2FY27 and H1FY27 financial results, which are being announced the same day. The call will be hosted by Motilal Oswal Securities Ltd. and represented by Managing Director Sandeep Singh, CEO Dr. Amrut Naik and Deputy CFO Dishant Hitesh Doshi. The filing contains no financial results or performance figures; it is an intimation of the investor call only.
- · Dial-in numbers: India +91 22 6280 1149 / +91 22 7115 8050; participants should dial in 10 minutes before the start time
- · Pre-registration available via the Diamond Pass link (Chorus Call) for express joining
04-11-2026
Biocon Limited notified the BSE and NSE that it has sent letters dated November 3, 2026 to shareholders whose FY 2025-26 final dividend is being withheld. Physical-form holders are withheld for incomplete KYC with RTA KFin Technologies, and demat-form holders for incomplete bank details with their depository participants. The final dividend is ₹0.50 per equity share (face value ₹5), approved at the 48th AGM held on August 6, 2026.
- · Letters to shareholders were dated October 30, 2026 and sent on November 3, 2026
- · Physical-form shareholders must submit Forms ISR-1 and ISR-2 with KFintech, including PAN linked to Aadhaar
- · Demat-form shareholders must complete bank name, account number, IFS code and bank address with their depository participants
- · Unclaimed dividends from prior years can be claimed after completing bank details
- · Shareholders are urged to dematerialise physical holdings, as physical transfers are not permitted
04-11-2026
Alkem Laboratories Ltd. has scheduled a conference call for investors and analysts on Thursday, November 12, 2026, from 4:30 pm to 5:30 pm IST to discuss its Q2 and H1FY27 financial results, which will be announced the same day. The call will be hosted by Motilal Oswal Securities Ltd. and represented by the Managing Director, CEO, and Deputy CFO. This filing is a scheduling intimation only and contains no financial results or performance figures.
- · Conference call dial-in available in India, international toll-free lines (USA, UK, Singapore, Hong Kong), and via Diamond Pass express join
- · Participants are asked to dial in 10 minutes before the scheduled start time
04-11-2026
Apollo Hospitals reported standalone unaudited results for Q2 FY27 (three months ended 30 September 2026), with revenue from operations of Rs 29,902 Million, up 26.9% YoY from Rs 23,561 Million, and profit after tax of Rs 4,757 Million, up 13.3% YoY from Rs 4,199 Million. Year-to-date (six months) revenue rose 22.9% to Rs 55,590 Million and PAT rose 18.4% to Rs 8,607 Million, but sequential QoQ profit rose 23.5% while employee costs and finance costs grew faster than revenue for the half year. The Board also completed the divestment of ASHPL and AFCPL to Kids Clinic India Limited (Cloudnine) for a 9.9% effective equity stake, and announced the cessation of Dr. Madhu Sasidhar as President & CEO - Hospitals Division effective 14 November 2026.
- · Standalone finance costs rose 19.5% YoY for six months to Rs 1,395 Million, and employee benefit expenses rose 18.4% to Rs 9,885 Million, growing in line with or faster than revenue growth of 22.9% only in part, compressing operating leverage on the staff line.
- · Cash and cash equivalents fell to Rs 2,767 Million from Rs 3,426 Million at 31 March 2026, and net cash decreased by Rs 659 Million in the period despite Rs 11,115 Million of operating cash flow, as capex of Rs 6,655 Million and debt repayments of Rs 977 Million absorbed funds.
- · Trade receivables rose to Rs 10,493 Million from Rs 8,473 Million at 31 March 2026 (about 24% increase), and other comprehensive loss widened to Rs (53) Million for six months.
- · Diluted EPS for the six months was Rs 59.82 versus Rs 50.55 in the prior-year period, up roughly 18%, while the three-month diluted EPS of Rs 29.20 compares with Rs 26.78 in Q1 FY27 (up about 9%).
- · The Q2 FY27 standalone PAT was flat on a sequential basis for the 2025 comparable only in the sense that the prior-year quarter EPS and related comparisons are not directly restated; the cessation of Dr. Madhu Sasidhar takes effect 14 November 2026, and support functions previously under the President & CEO move to the Project Management Office under the Managing Director.
04-11-2026
Max Healthcare Institute Limited has disclosed under Regulation 30 that its representatives will attend two physical investor conferences: the Goldman Sachs 15th India CIO Tour on November 13, 2026 (group meeting, The Oberoi, New Delhi) and the CITIC CLSA India Forum on November 17, 2026 (one-on-one and group meetings, Trident, Nariman Point, Mumbai). The company states that no unpublished price sensitive information will be shared and that the schedule is subject to change.
- · Goldman Sachs 15th India CIO Tour meeting is scheduled for November 13, 2026 (Friday) at The Oberoi, New Delhi
- · CITIC CLSA India Forum meeting is scheduled for November 17, 2026 (Tuesday) at Trident, Nariman Point
- · The CITIC CLSA engagement includes both one-on-one and group meetings
- · The company confirmed no unpublished price sensitive information (UPSI) will be shared at these conferences
- · The disclosure is also hosted on the company website, www.maxhealthcare.in
- · Ticker symbol MAXHEALTH (NSE) and scrip code 543220 (BSE)
05-11-2026
Apollo Hospitals filed its Investor Presentation for the three and six months ended September 30, 2026 (Q2 FY27). Consolidated revenue rose 23% YoY to ₹76,149 Mio and PAT grew 32% YoY to ₹6,301 Mio, while Healthcare Services EBITDA margin was 24.0%. Performance was mixed: Offline Pharmacy Distribution EBITDA margin was only 7.1% and Online PD & 24|7 remained loss-making at ₹(127) Mio versus ₹(710) Mio a year earlier, and AHLL's revenue growth of 20% was offset by completion of its stake transfer in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026, which is now reported as discontinued operations.
- · Online PD & 24|7 EBITDA loss narrowed sharply to ₹(127) Mio from ₹(710) Mio YoY, though margin remains negative
- · Offline PD EBITDA margin of 7.1% and Online PD & 24|7 margin of 5.9% are thin compared with Healthcare Services at 24.0%
- · Digital Cash recorded a profit of ₹13 Mio in Q2 FY27 (excluding ESOP charges), versus a loss of ₹83 Mio for H1 FY27 (excluding ESOP charges)
- · ASPL (Cradle) and AFCPL (Fertility) were transferred to Kids Clinic India Limited on October 12, 2026, classified as discontinued operations with comparatives re-presented
- · H1 FY27 consolidated revenue of ₹145,468 Mio grew 22% and PAT of ₹12,106 Mio grew 33% YoY
- · Healthcare Services occupancy at 73% (Q2 FY27) versus 76% in the prior comparison; 5 new hospitals (Pune, Defence Colony, Gachibowli, Sonarpur, Belenus) recently commissioned
04-11-2026
Torrent Pharmaceuticals Limited disclosed under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, that its Registrar and Share Transfer Agent, KFin Technologies Limited, will relocate its Corporate Office from Gachibowli, Hyderabad to Kokapet, Hyderabad effective 1st December 2026. The Registered Office of KFin remains unchanged, and investors are asked to update correspondence records accordingly. This is an administrative notice with no financial impact on Torrent Pharmaceuticals.
- · Effective date of RTA office relocation: 1st December 2026
- · New RTA Corporate Office address: 6th, 23rd, 24th, 25th Floor, South Tower, Rajapushpa West Avenue, Survey No. 115, Kokapet, Serilingampally Mandal, Ranga Reddy District, Hyderabad – 500075, Telangana
- · RTA intimation to the company was dated 2nd November 2026
- · Torrent Pharmaceuticals BSE Scrip Code: 500420; NSE Scrip Code: TORNTPHARM
04-11-2026
Sun Pharmaceutical Industries held its Q2 FY27 earnings call on October 30, 2026, reporting consolidated sales of INR1,61,000 million (up 11.8% YoY), gross margin of 80.8%, EBITDA of INR47,439 million (up 4.8% YoY, margin 29.3%, lower YoY partly due to a lenalidomide benefit in Q2 FY26), and reported PAT of INR19,885 million versus adjusted PAT of INR31,620 million with EPS of INR8.3. US sales declined 8.2% to USD455 million on lenalidomide erosion, with Ilumya slowing materially, while India formulations grew 17.3% to INR55,523 million and emerging markets grew 7.6% to USD350 million. The Organon acquisition is on track to close in Q4 FY27, and an ophthalmic production halt at the Assam plant following voluntary recalls of 11 products was discussed.
- · Management said Ilumya US growth slowed due to a mix of market factors and execution issues, with interventions in place and expected return to typical growth 'over the next few quarters'
- · Q2 FY27 R&D spend of INR7,784 million was below intended levels; management expects H2 catch-up, with R&D guidance of 6% to 7% referenced by an analyst but not reconfirmed in numeric terms by management
- · Organon acquisition expected to close in Q4 FY27 and is subject to remaining customary closing conditions; further acquisition-related exceptional costs are expected until closing
- · Management stated FY27 guidance remains as given at the beginning of the year, with no updated numeric guidance provided
- · Ophthalmic products recall: 11 products voluntarily recalled and manufacturing temporarily ceased at the Assam plant; management declined to comment on media reports of a regulator directive
- · US government agreement extends MFN pricing to state Medicaid programs, delays Section 232 tariffs on innovative products by over 2 years, and exempts Sun from GLOBE and GUARD Medicare models
- · India volume growth was 6.7% versus IPM growth of 1.8%; management said roughly 50% to 60% of India growth came from volume plus new products, with the rest from pricing
- · Constant-currency emerging markets growth was 7.4%; Rest of World growth was lower and management did not guide to specific growth numbers
- · Gross margin benefited from better product mix and favorable currency tailwinds; EBITDA margin declined YoY partly due to lenalidomide sales in Q2 FY26
04-11-2026
Zydus Lifesciences Limited has filed a regulatory disclosure under Regulations 30 and 46(2)(oa) of the SEBI Listing Regulations, 2015, confirming that the audio recording of its investor call on the unaudited financial results for the quarter and half year ended September 30, 2026 is available on the company's website. The filing contains no financial figures, performance metrics, or guidance; the substantive results are not disclosed in this document.
- · Investor call discussed unaudited financial results for the quarter and half year ended September 30, 2026
- · Audio recording of the investor call dated November 4, 2026 is hosted on the company website as an MP3 file
- · Filing made under Regulations 30 and 46(2)(oa) of the SEBI Listing Regulations, 2015
- · Filing addressed to BSE (Scrip Code 532321) and NSE (Symbol ZYDUSLIFE)
04-11-2026
Glenmark Pharmaceuticals disclosed that its subsidiary Ichnos Glenmark Innovation (IGI) will present updated Phase 1 TRIgnite-1 clinical data for ISB 2001 (ABBV-2001), a CD38 x BCMA x CD3 trispecific T-cell engager, in relapsed/refractory multiple myeloma as an oral presentation at the 68th ASH Annual Meeting on December 12, 2026. The update includes longer follow-up from dose escalation and early dose-expansion results, and the asset is partnered with AbbVie under an exclusive global licensing agreement signed in July 2025. The filing is a promotional scientific update with no financial figures, guidance, or deal terms disclosed.
- · Oral presentation scheduled for Saturday, December 12, 2026, 4:00-4:15 pm CST at La Nouvelle C, Ernest N. Morial Convention Center, New Orleans (Session 654)
- · IGI and AbbVie signed an exclusive global licensing agreement for the trispecific in July 2025
- · ISB 2001 is described as the first and only-in-class CD38 x BCMA x CD3 trispecific T-cell engager
04-11-2026
Aurobindo Pharma reported unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, with consolidated revenue from operations of ₹10,263.3 Cr in Q2 FY27 (up from ₹8,285.7 Cr in Q2 FY26, +23.9% YoY) and consolidated PAT of ₹1,123.8 Cr (up from ₹848.1 Cr, +32.5% YoY); growth was supported by the Lannett acquisition consolidated from June 29, 2026, which makes the results not fully comparable to prior periods. Standalone revenue from operations rose 16.4% YoY to ₹3,177.3 Cr and standalone PAT rose 24.3% YoY to ₹723.6 Cr, while standalone other income fell sharply and total expenses grew faster than revenue in some lines. The Board also declared an interim dividend of ₹7 per equity share.
- · Consolidated total comprehensive income rose to ₹1,326.8 Cr in Q2 FY27 from the ₹985.2 Cr reported in Q1 FY27, but declined from ₹1,389.2 Cr in Q2 FY26 due to a large foreign-exchange translation gain in the prior-year quarter.
- · Standalone other income fell to ₹102.8 Cr in Q2 FY27 from ₹159.5 Cr in Q2 FY26, a decline of about 35.5%, while standalone employee benefit expenses grew about 8.5% YoY to ₹300.1 Cr.
- · Consolidated other expenses included a ₹43.3 Cr net loss on derecognition of lease receivable at Aurobindo Pharma USA, Inc. during the half year.
- · Consolidated exceptional items of ₹40.2 Cr relate to Lannett acquisition and related costs in the half year ended September 30, 2026.
- · Standalone cash and cash equivalents fell to ₹97.4 Cr at September 30, 2026 from ₹160.4 Cr at March 31, 2026, while standalone trade receivables rose to ₹4,992.0 Cr from ₹4,209.7 Cr.
- · Consolidated Lannett goodwill of ~₹460.3 Cr (USD 48.7 Mn) and fair value of net assets acquired of ~₹1,861.6 Cr (USD 197.0 Mn) are provisional, and the purchase consideration was ~₹2,321.8 Cr (USD 245.7 Mn).
- · The auditors issued an unmodified conclusion on both standalone and consolidated results, but the consolidated review excluded 22 subsidiaries reviewed by other auditors and 65 subsidiaries not reviewed by their auditors.
- · Pending regulatory approvals, the NCLT-approved amalgamation schemes have had no impact given in the current results.
04-11-2026
Aurobindo Pharma reported record Q2FY27 consolidated revenue from operations of INR 10,263 Cr, up 23.9% YoY and 12.2% QoQ, with net profit of INR 1,124 Cr (up 32.5% YoY) and EBITDA margin expanding 75 bps YoY to 21.0%. Growth was broad-based, though Growth Markets slowed to a 3.5% QoQ decline and ARV revenue grew only 10.2% YoY and was described as broadly stable. The company also declared an interim dividend of INR 7.0 per share and will hold an earnings call on 05-Nov-26.
- · Revenue mix: US 44%, Europe 31%, Growth Markets 10%, ARV 3%, API 11% of consolidated revenue
- · Q2FY27 Growth Markets revenue declined 3.5% QoQ, and Non Beta-lactam API grew 11.3% YoY versus 20.9% total API growth
- · Net Profit 'PBT before share of P/L of JV' rose 32.7% YoY and 11.5% QoQ
- · Basic and Diluted EPS stood at INR 19.57 per share
- · Q2FY27 R&D expenditure rose to INR 376 Cr from INR 344 Cr in the prior quarter
- · Earnings call scheduled for 8:30 AM IST on 05-Nov-26
04-11-2026
Aurobindo Pharma's Board approved an interim dividend of Rs. 7.00 per equity share of Re. 1 (700% of face value) for FY 2026-27, with November 11, 2026 as the record date and payment on or before November 20, 2026. The decision was taken at a Board meeting held on November 4, 2026, which ran from 4:15 p.m. to 6:00 p.m. The filing contains no period-over-period financial performance data.
- · Record date for interim dividend entitlement: November 11, 2026
- · Interim dividend payment deadline: on or before November 20, 2026
- · Board meeting held November 4, 2026, from 4:15 p.m. to 6:00 p.m.
04-11-2026
Torrent Pharmaceuticals Limited informed BSE and NSE that newspaper advertisements regarding a special window for transfer and dematerialisation requests of physical shares were published in Financial Express (English and Gujarati) on 03-Nov-26. The filing is administrative in nature and contains no financial results, guidance, or material business developments.
- · BSE Scrip Code: 500420; NSE Scrip Code: TORNTPHARM
- · Newspaper cuttings published in Financial Express in English and Gujarati on 03-Nov-26
- · Investor queries directed to [email protected]
04-11-2026
04-11-2026
Aurobindo Pharma Ltd (BSE: 524804) has filed an intimation of record date for payment of interim dividend for FY 2026-2027, dated November 04, 2026. The filing itself does not disclose the dividend amount per share, record date, or payment date in the provided summary; these details are NOT_DISCLOSED in the source text. Financial performance metrics are not included in the filing summary.
- · Dividend amount per share, record date, payment date, and total payout are NOT_DISCLOSED in the provided summary; the full BSE filing should be reviewed
- · Sector is not specified in the source data; Aurobindo Pharma is generally classified in pharmaceuticals, which should be confirmed
04-11-2026
Aurobindo Pharma's Board, at its November 4, 2026 meeting, approved the re-appointment of Mr. Mangalam Ramasubramanian Kumar (DIN 03628755) as Non-executive and Independent Director for a second five-year term effective April 1, 2027, subject to member approval by postal ballot/special resolution. His first term concludes March 31, 2027, and the filing affirms he is unrelated to other directors/KMP and not debarred by SEBI. No financial metrics are disclosed.
- · Board meeting commenced at 4:15 p.m. and concluded at 6:00 p.m. on November 4, 2026
- · Nominee is a Science graduate from University of Madras and joined LIC of India in 1983; served as Chairman of LIC of India from March 2019 to March 2023
- · Nominee is currently a director of Cholamandalam Investment and Finance Company Limited, Aurobindo Pharma USA Inc., and Non-executive Chairman of Bank of India
- · Director is entitled to sitting fees for board and committee meetings plus commission; not liable to retire by rotation
- · Disclosure made under Regulation 30 and Part A of Schedule III of SEBI LODR Regulations, 2015
04-11-2026
Aurobindo Pharma's board approved, on November 4, 2026, the transfer of 100% ownership of Auro Pharma LLC, Russia, from Auroactive Pharma Private Limited to Auropharm Overseas Limited, both wholly owned subsidiaries of the Company, as part of an internal reorganization of its Russian holdings. The cash consideration is approximately INR 29 crore, subject to adjustments as agreed between the parties on the transfer date, and completion is expected within 60-90 days. Auro Pharma LLC reported nil turnover for FY2026, FY2025 and FY2024, while the transferring subsidiary Auroactive Pharma reported FY2026 turnover of INR 701.3 million.
- · Board meeting commenced at 4:15 p.m. and concluded at 6:00 p.m. on November 4, 2026
- · Auro Pharma LLC was incorporated on July 24, 2023 in Russia and is a step-down subsidiary engaged in manufacturing and marketing pharmaceutical products
- · The transaction is exempt from related party transaction provisions under Regulations 23(2), (3) and (4) of SEBI LODR as it is between wholly owned subsidiaries
- · No governmental or regulatory approvals are required for the transfer
- · Auro Pharma LLC has generated nil turnover since incorporation, so the transfer carries no revenue impact
04-11-2026
Aurobindo Pharma reported Q2 FY27 (quarter ended 30 September 2026) standalone revenue from operations of ₹31,773.3 million, up 16.5% YoY from ₹27,299.3 million, and standalone PAT of ₹7,235.8 million, up 24.3% YoY from ₹5,813.7 million. Consolidated revenue from operations for the quarter was ₹1,02,632.9 million, up 23.9% YoY, with consolidated PAT of ₹11,238.4 million, up 32.5% YoY, aided by the Lannett Company LLC acquisition completed on June 29, 2026. Results were mixed on a sequential basis: standalone other income fell 57.5% QoQ and standalone PAT was broadly flat (down 1.9% QoQ), and the Board declared an interim dividend of ₹7 per share.
- · Standalone other income fell from ₹2,418.9 Mn in Q1 FY27 to ₹1,028.0 Mn in Q2 FY27, a 57.5% sequential decline, driven by lower other income and a sharp decline in foreign exchange gains.
- · Standalone changes in inventories swung to ₹777.2 Mn in Q2 FY27 from ₹(480.5) Mn in Q1 FY27, and standalone employee benefit expense rose 1.4% QoQ to ₹3,000.7 Mn.
- · Consolidated other income rose to ₹1,682.2 Mn in Q2 FY27 from ₹1,205.9 Mn in Q2 FY26 (+39.5% YoY), while consolidated Q2 FY27 finance costs of ₹1,022.1 Mn were up 7.3% YoY.
- · Consolidated net cash generated from operating activities was ₹32,831.4 Mn for the half year ended September 30, 2026, up 13.8% from ₹28,850.6 Mn in the prior-year half.
- · Consolidated net cash used in investing activities was ₹37,022.1 Mn for the half year, versus ₹22,234.1 Mn in the prior-year half, reflecting the Lannett acquisition and capex.
- · Standalone trade receivables rose to ₹49,920.3 Mn at September 30, 2026 from ₹42,096.8 Mn at March 31, 2026 (+18.6% in six months), and standalone cash and cash equivalents fell to ₹973.9 Mn from ₹1,604.3 Mn.
- · Consolidated cash and cash equivalents declined to ₹62,315.1 Mn from ₹71,914.0 Mn at March 31, 2026, while consolidated borrowings rose to ₹72,518.2 Mn (current) from ₹68,734.5 Mn.
- · The Lannett acquisition (purchase consideration ₹23,218.3 Mn / USD 245.7 Mn) yielded goodwill of ₹4,602.7 Mn (USD 48.7 Mn); the initial purchase accounting is provisional, and results are not comparable to prior periods.
- · Exceptional item of ₹401.8 Mn (USD 4.3 Mn) in the half year relates to acquisition and related costs for Lannett.
- · Net loss of ₹432.6 Mn (USD 4.5 Mn) on derecognition of lease receivable at Aurobindo Pharma USA, Inc. was recorded in other expenses in the half year.
- · Standalone interim dividend of ₹7 per share declared by the Board on November 4, 2026.
- · Share buyback completed: 5,423,728 shares (0.93% of equity) for an aggregate ₹8,058 Mn including expenses, reducing paid-up equity share capital by ₹5.4 Mn standalone.
- · Consolidated equity attributable to owners of the parent rose to ₹3,93,999.0 Mn at September 30, 2026 from ₹3,78,909.7 Mn at March 31, 2026.
- · Standalone EPS for Q2 FY27 was ₹12.58 basic and diluted, up from ₹10.01 in Q2 FY26 (+25.7% YoY).
- · Auditors (Deloitte Haskins & Sells) issued an unmodified conclusion on both the standalone and consolidated limited reviews; the consolidated review excluded 22 subsidiaries reviewed by other auditors and 65 subsidiaries reviewed by management only.
- · Scheme of Amalgamation filings are pending before NCLT for Curateq/Auro Vaccines and Eugia entities; no impact has been recognized pending regulatory approvals.
04-11-2026
Biocon Limited filed a Regulation 30 intimation with BSE and NSE confirming that audio and video recordings of its Q2 FY27 earnings call, held on November 04, 2026, are available via a link on the company's investor relations website. The filing contains no financial results, operating metrics, or guidance; it is a procedural disclosure only.
- · Earnings call reference: Q2 FY27, conducted November 04, 2026
- · Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015
- · Scrip code BSE 532523; NSE symbol BIOCON
- · Recordings hosted at biocon.com investor relations, quarterly reports section for FY 2026-27
04-11-2026
Dr. Reddy's Laboratories responded to a BSE surveillance query about a November 3, 2026 FirstPost article reporting U.S. FDA tentative approval for its generic twice-yearly injectable lenacapavir, an HIV prevention shot intended for 120 lower-income countries outside the US. The company confirmed the headline reflects its November 2, 2026 press release and stated the matter is not a material event requiring disclosure under Regulation 30 of the SEBI Listing Regulations.
- · US FDA granted tentative approval for the product, announced in a press release dated November 2, 2026
- · The company explicitly stated the matter does not constitute a material event under Regulation 30
- · BSE Surveillance had sought clarification via e-mail dated November 3, 2026
04-11-2026
GlaxoSmithKline Pharmaceuticals Limited filed its Q2 FY27 investor/analyst presentation on November 4, 2026. Standalone revenue reached ₹1180cr, up 21% YoY, with H1 revenue of ₹2104cr (+18%). EBITDA was ₹400cr in Q2 (+33%) at a 34% margin, down 50 bps YoY, while PAT was ₹335cr (+20%... see note) with the PAT margin rising 260 bps to 29%, aided partly by an income tax refund. The company shows mixed performance: Q2 EBITDA margin contracted while several GSK India brands and categories saw flat or declining share and volume.
- · Q2 FY27 PAT margin expansion (+260 bps) was partly supported by interest income on an income tax refund received during the quarter, not purely operating improvement.
- · Q2 EBITDA margin contracted 50 bps YoY due to gross margin dilution from currency depreciation, higher depreciation and input costs, partially offset by price increases and SG&A reduction of ~1% of sales.
- · Several established vaccine and general medicine brands lost unit market share in Q2 FY27, including Fluarix (-5.2%), Boostrix (-3.6%), Calpol (-3.0%) and Augmentin (-1.0%), while Havrix and Ceftum were flat.
- · Innovation portfolio (Oncology, New Respiratory, Adult Vaccines) accounted for 7% of total sales versus 3% in the prior year.
- · GSK India's Q2 FY27 IPM growth (14.7%) was driven largely by price; volume growth was 2.3% and new-to-industry contribution was 5.3%.
04-11-2026
Cipla Limited's Board of Directors has approved the appointment of Mr Vikram Janakiraman as Global Chief Technical Operating Officer, designated as Senior Management Personnel, effective 7 December 2026. He joins from Boston Consulting Group, where he was Managing Director and Senior Partner, and previously held manufacturing, supply chain and procurement leadership roles at Glenmark Pharmaceuticals. The filing contains no financial results or quantitative performance data.
- · Appointment is effective 7 December 2026, full-time employment
- · Executive previously led Manufacturing, Supply Chain, Procurement and Capital Projects globally at Glenmark, supporting USFDA, MHRA and ANVISA inspections
- · Disclosure made under Regulation 30 of SEBI Listing Regulations; no relationships between directors disclosed
04-11-2026
Biocon Limited filed its Q2 FY27 earnings call presentation with BSE and NSE on November 04, 2026. Consolidated Revenue from Operations rose 2% YoY to ₹4,389 Cr, but EBITDA fell 7% YoY to ₹865 Cr (20% margin vs 22%) and Profit Before Tax (before exceptional items) fell 66% YoY to ₹62 Cr. Biosimilars revenue grew 3% YoY to ₹2,809 Cr while Services revenue declined 9% YoY to ₹833 Cr, and management characterised FY27 as a transition year with a stronger H2 expected.
- · Q2 FY27 Services EBITDA margin was 20% vs 23% in Q2 FY26, and Biosimilars EBITDA fell 14% QoQ to ₹623 Cr
- · Generics Q2 FY27 EBITDA rose to ₹64 Cr from ₹7 Cr in Q2 FY26, with EBITDA margin improving over 700bps YoY
- · Biosimilars reported growth and margins were impacted by timing of revenue recognition on certain shipments
- · H1 FY27 Net Profit (before exceptional items) rose 42% YoY to ₹189 Cr despite Profit Before Tax falling 32% YoY to ₹203 Cr
- · Q2 FY27 Net Profit (before exceptional items) fell 70% QoQ from ₹145 Cr in Q1 FY27
- · Q2 FY27 R&D (Net) declined 6% YoY to ₹237 Cr
- · Services segment is described by management as a transition year for FY27, with further improvement expected in H2
Get daily alerts with 13 investment signals, 9 risk alerts, 9 opportunities and full AI analysis of all 44 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: BSE Pharma Sector Regulatory Filings
🇮🇳 More from India
View all →November 05, 2026
India Upcoming Corporate Actions BSE NSE — November 05, 2026
India Upcoming Corporate Actions BSE NSE
November 05, 2026
India Pre-Market Regulatory Roundup — November 05, 2026
India Pre-Market Regulatory Roundup
November 05, 2026
India Quarterly Results BSE NSE Announcements — November 05, 2026
India Quarterly Results BSE NSE Announcements
November 05, 2026
India NCLT Insolvency Resolution Filings — November 05, 2026
India NCLT Insolvency Resolution Filings